• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med COVID-19 Related Coagulopathy: A Distinct Entity?

tetano

Editor, Senior Moderator
J Clin Med


. 2020 May 31;9(6):E1651.
doi: 10.3390/jcm9061651.
COVID-19 Related Coagulopathy: A Distinct Entity?


Benjamin Marchandot[SUP] 1 [/SUP], Laurent Sattler[SUP] 2 [/SUP], Laurence Jesel[SUP] 1 3 [/SUP], Kensuke Matsushita[SUP] 1 3 [/SUP], Valerie Schini-Kerth[SUP] 3 [/SUP], Lelia Grunebaum[SUP] 2 [/SUP], Olivier Morel[SUP] 1 3 [/SUP]



Affiliations
Free article

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has impacted healthcare communities across the globe on an unprecedented scale. Patients have had diverse clinical outcomes, but those developing COVID-19-related coagulopathy have shown a disproportionately worse outcome. This narrative review summarizes current evidence regarding the epidemiology, clinical features, known and presumed pathophysiology-based models, and treatment guidance regarding COVID-19 coagulopathy.

Keywords: COVID-19; antiphospholipid antibodies; coronavirus disease 2019; endothelium; hemostasis; microparticles; thrombosis.
 
Back
Top Bottom